India’s top excipient player scales new verticals with the launch of a 25-acre API and specialty chemical site while maintaining its global MCC leadership.
Sigachi Industries Ltd., India’s largest manufacturer of Microcrystalline Cellulose (MCC), has announced the next phase of its expansion with the establishment of a bulk drugs and specialty chemicals facility in Orvakal, Andhra Pradesh. This vertically integrated move signals the company’s diversification into regulated Active Pharmaceutical Ingredients (APIs) and strengthens its capacity to serve global pharma and nutraceutical clients.
Sigachi has received Terms of Reference (ToR) approval from SEIAA, Andhra Pradesh, and will initiate its Environment Clearance (EC) process from July 15, 2025. Development is scheduled to begin on August 1, 2025.
New API Facility: Sigachi Orvakal Node
The new site spans over 25 acres in the Guttapadu-Orvakal industrial corridor. It is designed to offer high-volume manufacturing with flexible regulatory alignment for both regulated and semi-regulated markets. The facility is positioned to enhance Sigachi’s R&D responsiveness, speed up commercialisation timelines, and cater to new therapeutic segments.
According to Mr. Amit Raj Sinha, Managing Director and CEO, “FY25 has been a transformative year. With Orvakal, we add depth to our infrastructure and scale to our ambition. This facility gives us room to serve new therapeutic spaces and increase our responsiveness to global demand.”
MCC: Sigachi’s Flagship Segment
Sigachi continues to lead the global excipient space with over 22,000 MTPA of MCC capacity, operating at over 80 percent utilisation. The company has developed more than 60 MCC grades under proprietary formulations, including its DAPOBAL process and acid recovery systems. MCC remains a key ingredient in oral solid dosage forms, and Sigachi’s offerings are widely used by both generics and innovators worldwide.
Its facilities hold certifications from USFDA, EDQM, EXCiPACT, ISO 9001, ISO 14001, and ISO 45001.
Financial Highlights
In FY25, Sigachi reported revenue of ₹5,003 million, reflecting 25.4 percent growth, with EBITDA up 46.2 percent. The company has maintained strong operating margins and low debt, with 28 percent PAT CAGR over five years.
Innovation and Pipeline
Sigachi operates two DSIR-certified R&D centers in Hyderabad and Dahej. Its current roadmap includes:
- Introduction of Croscarmellose Sodium (CCS)
- Expansion of co-processed MCC variants
- Entry into 3D-printed pharmaceutical applications
- Launch of an API-focused R&D and analytics hub by FY26
